Amgen vs Axsome: Stability vs Growth in Healthcare Stocks

When it comes to healthcare stocks, two companies that have recently caught investors' attention are Amgen (AMGN) and Axsome Therapeutics (AXSM). While Amgen is a well-established pharmaceutical giant with a diverse portfolio, Axsome is a smaller biopharmaceutical company specializing in central nervous system disorders.

Amgen operates on a massive scale, distributing its products to approximately 100 countries. In fiscal year 2025, the company reported revenue of nearly $36.7 billion, a 9.9% increase from the previous year. Its net income was around $7.7 billion, resulting in a net margin of 21%. However, Amgen's debt-to-equity ratio is high at 6.3, indicating that total debt exceeds six times shareholder equity.

Axsome Therapeutics, on the other hand, has seen rapid growth, with revenue increasing by approximately $638.5 million in fiscal year 2025, a 65.5% year-over-year increase. Despite this strong top-line growth, Axsome reported a net loss of nearly $183.2 million as it continues to invest in its pipeline.

One key difference between the two companies is their risk profile. Amgen faces significant pricing pressure from government and commercial payers, patent litigation, and manufacturing concentration in Puerto Rico, which is susceptible to natural disasters. Axsome, while having a smaller product portfolio and an accumulated deficit of nearly $1.3 billion, has a relatively low debt-to-equity ratio of 2.7.

Valuation-wise, Amgen trades at a significantly lower multiple than Axsome, with a forward P/E ratio of 19.1 compared to Axsome's 4.5. Considering these factors, investors may want to weigh the established stability of Amgen against the potential for rapid growth and long-term profitability at Axsome.